Ftse Mib
34.252,16
-0,36%
DAX
18.487,11
-0,61%
S&P 500
5.631,22
0,28%
NASDAQ
18.472,57
0,00%
Bitcoin
63.887,04
-1,49%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. AMEX BioPharmX Corporation (BPMX) BioPharmX Corporation (BPMX) Notizie

BPMX

BioPharmX (BPMX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:AMEX:BPMX
DataOraFonteTitoloSimboloCompagnia
18/03/201911:45PR Newswire (US)BioPharmX to Participate in the 31st Annual ROTH Conference and the Oppenheimer 29th Annual Healthcare ConferenceAMEX:BPMXBioPharmX Corporation
14/03/201921:31Edgar (US Regulatory)Annual Report (10-k)AMEX:BPMXBioPharmX Corporation
14/03/201921:09Edgar (US Regulatory)Current Report Filing (8-k)AMEX:BPMXBioPharmX Corporation
14/03/201921:05PR Newswire (US)BioPharmX Reports Fourth Quarter and Full Year 2019 Financial ResultsAMEX:BPMXBioPharmX Corporation
04/03/201912:00PR Newswire (US)BioPharmX Completes Enrollment in Phase 2b Trial of BPX-04 for Patients with Papulopustular RosaceaAMEX:BPMXBioPharmX Corporation
27/02/201922:15PR Newswire (US)BioPharmX Receives Notice of Compliance Deadline Extension from NYSE AmericanAMEX:BPMXBioPharmX Corporation
22/02/201900:37Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)AMEX:BPMXBioPharmX Corporation
22/02/201900:27Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)AMEX:BPMXBioPharmX Corporation
14/02/201921:33Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)AMEX:BPMXBioPharmX Corporation
14/02/201912:50Edgar (US Regulatory)Notice of Effectiveness (effect)AMEX:BPMXBioPharmX Corporation
04/02/201913:00PR Newswire (US)BioPharmX Strengthens Board of Directors with Appointment of Industry Veteran Dr. R. Todd PlottAMEX:BPMXBioPharmX Corporation
31/01/201923:31Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)AMEX:BPMXBioPharmX Corporation
20/12/201822:30PR Newswire (US)BioPharmX Receives Notice of Noncompliance from NYSE AmericanAMEX:BPMXBioPharmX Corporation
07/12/201822:10Edgar (US Regulatory)Quarterly Report (10-q)AMEX:BPMXBioPharmX Corporation
07/12/201821:09Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)AMEX:BPMXBioPharmX Corporation
06/12/201822:10PR Newswire (US)BioPharmX Reports Third Quarter 2019 Financial ResultsAMEX:BPMXBioPharmX Corporation
16/11/201812:00PR Newswire (US)BioPharmX Announces NYSE American Acceptance of Plan To Regain Listing ComplianceAMEX:BPMXBioPharmX Corporation
11/10/201822:30PR Newswire (US)BioPharmX Initiates Phase 2b Trial of BPX-04 for RosaceaAMEX:BPMXBioPharmX Corporation
12/09/201823:30PR Newswire (US)BioPharmX Corporation Announces David S. Tierney, M.D. Joined the Company as Chief Executive OfficerAMEX:BPMXBioPharmX Corporation
10/09/201822:08Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)AMEX:BPMXBioPharmX Corporation
30/08/201822:15PR Newswire (US)BioPharmX Reports Second Quarter 2019 Financial ResultsAMEX:BPMXBioPharmX Corporation
15/08/201800:00PR Newswire (US)BioPharmX Announces Results of Annual Shareholders MeetingAMEX:BPMXBioPharmX Corporation
09/08/201812:15PR Newswire (US)BioPharmX Announces Patent Award, Expanding Protection for Innovations in Solid Dosage FormsAMEX:BPMXBioPharmX Corporation
31/07/201815:15PR Newswire (US)BioPharmX Receives IRB Approval to Initiate Phase 2 Trial of BPX-04 for the Treatment of RosaceaAMEX:BPMXBioPharmX Corporation
19/07/201815:15PR Newswire (US)BioPharmX Announces FDA Grant of CARC Waiver and Post-Hoc Analysis for BPX-01AMEX:BPMXBioPharmX Corporation
06/07/201814:03Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)AMEX:BPMXBioPharmX Corporation
26/06/201822:08Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)AMEX:BPMXBioPharmX Corporation
19/06/201815:15PR Newswire (US)New Patient-Centered Panel Helps BioPharmX Define its Role in the Future of DermatologyAMEX:BPMXBioPharmX Corporation
07/06/201822:15PR Newswire (US)BioPharmX Reports First Quarter 2019 Financial ResultsAMEX:BPMXBioPharmX Corporation
24/05/201815:00PR Newswire (US)BioPharmX Studies Show Hydrophilic Topical Minocycline Gels May Be the Preferred Treatment Option for Acne, Rosacea PatientsAMEX:BPMXBioPharmX Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:AMEX:BPMX

La tua Cronologia

BIT
P21RR7
NLBNPIT21RR7 20991231 23...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network